Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00709462 · ClinicalTrials.gov registry record · Phase 1

A Study of CDX-1307, in Patients With Incurable Breast, Colorectal, Pancreatic, Ovarian or Bladder Cancer (CDX 1307-01)

A Phase 1 study of Breast Cancer and Colorectal Cancer, sponsored by Celldex Therapeutics.

Completed
Registry status
Phase 1
Development phase
48
Enrollment target
3
Study locations

NCT00709462 is a Phase 1 study of Breast Cancer and Colorectal Cancer that has completed, run by Celldex Therapeutics. The registered enrollment target is 48 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (98% lower). The trial reports 3 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00709462, a Phase 1 study of Breast Cancer and Colorectal Cancer, has completed, sponsored by Celldex Therapeutics.

COMPLETED
Registry status
Phase 1
Development phase
48 participants
Enrollment target
3
Study locations

Study Summary

This research study is for individuals who have advanced breast, colon, pancreatic, ovarian or bladder cancer. Celldex Therapeutics, Inc. is testing a form of immune therapy (vaccine) to see if it can be used to make the immune system attack the cancer. The study includes administration of additional treatments, in combination, thought to enhance the immune response effect. (CDX 1307-01)

Conditions Studied

Breast Cancer Colorectal Cancer Ovarian Cancer Pancreatic Cancer Bladder Cancer

Interventions

  • BIOLOGICAL CDX1307

Study Locations (3)

North Carolina

  • Duke University - Durham
  • Carolina BioOncology Institute Cancer - Huntersville

Michigan

  • Henry Ford Health System - Detroit

Trial Details

FieldValue
Enrollment Target 48 participants
Start Date 2004-03
Est. Completion 2010-06
Phase Phase 1

Sponsor

Celldex Therapeutics

42 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00709462

The ClinicalTrials.gov registry entry for NCT00709462 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (98% lower). The listed sponsor is Celldex Therapeutics, which has 42 total studies on file at ClinicalTrials.gov.

The record links to 5 conditions, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which CDX1307 is the first listed.

NCT00709462 reports 3 study locations spanning 2 distinct geographic areas - top geographies include North Carolina, Michigan.

Frequently Asked Questions

What is clinical trial NCT00709462 about?

NCT00709462 is a clinical study titled "A Study of CDX-1307, in Patients With Incurable Breast, Colorectal, Pancreatic, Ovarian or Bladder Cancer (CDX 1307-01)". This research study is for individuals who have advanced breast, colon, pancreatic, ovarian or bladder cancer. Celldex Therapeutics, Inc. is testing a form of immune therapy (vaccine) to see if it can be used to make the immune system attack the cancer. The study includes administration of additiona...

What is the current status of trial NCT00709462?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2004-03. Estimated completion is 2010-06.

What conditions does trial NCT00709462 study?

This clinical trial studies the following conditions: Breast Cancer, Colorectal Cancer, Ovarian Cancer, Pancreatic Cancer, Bladder Cancer.

What interventions are being tested in trial NCT00709462?

The interventions under investigation include: CDX1307 (BIOLOGICAL).

Who is sponsoring clinical trial NCT00709462?

This trial is sponsored by Celldex Therapeutics, which has 42 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00709462 being conducted?

This trial has 3 study locations across Michigan, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Breast Cancer

All registered trials for this condition

Colorectal Cancer

All registered trials for this condition

Michigan

All trials with a study site in Michigan

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.